Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4434992 | 0.81 | PARP1 (1.00) | PARP1 | |
| SCHEMBL2205818 | 0.80 | PARP1 (0.66) | PARP1 | |
| SCHEMBL12431791 | 0.80 | PARP1 (0.66) | PARP1 | |
| SCHEMBL4440345 | 0.80 | PARP1 (1.00) | PARP1 | |
| SCHEMBL4555601 | 0.79 | PARP1 (1.00) | PARP1 | |
| SCHEMBL4445245 | 0.78 | PARP1 (1.00) | PARP1 | |
| SCHEMBL4438636 | 0.78 | PARP1 (1.00) | PARP1 | |
| SCHEMBL4438330 | 0.78 | PARP1 (1.00) | PARP1 | |
| SCHEMBL4435940 | 0.77 | PARP1 (1.00) | PARP1 | |
| SCHEMBL4439351 | 0.77 | PARP1 (1.00) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981890-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2011-07-19 | — | — | US | disclosed |
| US-7981890-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2011-07-19 | — | — | US | disclosed |
| US-7981890-B2 | Phthalazinone derivatives | ASTRAZENECA AB (SE) | 2011-07-19 | — | — | US | disclosed |
| EP-2188278-A1 | PHTHALAZINONE DERIVATIVES | AstraZeneca AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| US-20090186897-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186897-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| US-20090186897-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| WO-2009034326-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009034326-A1 | PHTHALAZINONE DERIVATIVES | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186897-A1 | PHTHALAZINONE DERIVATIVES | RCC2, CBR1, RCC1 | PARP1 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.